

Faron Pharmaceuticals

Company report

08/26/2022



Antti Siltanen
+358 45 119 6869
antti.siltanen@inderes.fi

✓ Inderes corporate customer

This report is a summary translation of the report “Yllätyksetön raportti pitää ennusteet ennallaan” published on 08/26/2022 at 7:30 am.

**inde
res.**

Unsurprising report keeps estimates unchanged

Faron's H1 report offered no surprises. The company didn't have any revenue as we expected, and the operating loss was in line with our forecasts. There was no significant new information on research or business progress, so we are not making any changes to the forecasts in our recently published extensive report. Our valuation relies heavily on a DCF calculation based on risk-adjusted estimates, which produces a present value of the stock that remains unchanged at EUR 2.8. In our view, peer analysis suggests a neutral valuation of the stock. We maintain our Buy recommendation for the share and keep the target price at EUR 2.8.

The figures were in line with our forecasts

As expected, Faron had no revenue in H1. The operating loss of EUR 13.4 million was in line with our forecasts and the financial reporting did not offer any other surprises. Faron's cash and cash equivalents at the end of H1 amounted to EUR 9.9 million and cash flow from operating activities to EUR -11.3 million. The company reiterated previous information on cash adequacy until Q1'23. Thus, we expect the company to make financial arrangements during H2. Possible arrangements could include a share issue or a commercialization agreement with a larger pharmaceutical company. Faron also signed a EUR 30 million debt agreement during the reporting period, of which the company has so far drawn down EUR 10 million. The remainder can be drawn down if the conditions of the debt agreement are met during this and next year.

A little extra light was shed on Traumakine plans

In terms of business development, new information was received about Traumakine drug candidate. In its H1 presentation, Faron announced plans to conduct a clinical trial starting in H1'23. The company said it plans the drug to be used for ischemia-reperfusion (i.e. the recovery of blocked blood flow) in organ damage. We await further details of the plans before modeling new uses in our estimates. In other respects, the company reported on the recently launched BEXMAB study (blood cancers) and the near-term plans for the MATINS study.

No significant changes in estimates and valuation

We are keeping our estimates virtually unchanged from the latest figures we presented in the extensive report. Our valuation is based on risk-weighted estimates that account for the risk of research failure. We discussed our estimate model in more detail in our recent [extensive report](#). In the absence of revenue and profitability, our view on the fair value of the stock is based on the DCF model and peer analysis. DCF indicates the share value of EUR 2.8. The median market value of the peers is EUR 81 million, below Faron's EUR 122 million. However, we believe Faron deserves a higher valuation than its peers based on its large target market and the potential of its three drug candidate programs. In our assessment, Faron is neutrally valued relative to its peers. Faron is a high-risk investment. Therefore, we remind investors of the importance of diversification, as the failure of drug development can lead to the ultimate loss of invested capital. In our view, the share offers sufficient expected return to compensate for taking on high risk.

Recommendation

Accumulate


(previous Accumulate)

2.80 EUR

(previous EUR 2.80)

Share price:

2.22



Guidance

Faron does not provide any guidance

Share price



Source: Millstream Market Data AB



Value drivers

- High need for new cancer drugs
- Target market is estimated to grow to USD 140 billion by 2030 (CAGR 16.8 %)
- Very defensive sector
- Possibility of globally sold medicines whose annual revenue potential is calculated in billions and Faron's cash flow in hundreds of millions
- Potential can also materialize through a cooperation agreement or acquisition



Risk factors

- Drug development requires substantial front-loaded investments
- Failed drug development is likely to result in permanent loss of invested capital
- Success depends on the safety and efficacy of drug candidates, which may prove insufficient in studies
- If market entry is successful, the market share, sales price and royalties involve uncertainties

Valuation	2022e	2023e	2024e
Share price	2.22	2.22	2.22
Number of shares, millions	55.3	55.3	55.3
Market cap	123	123	123
EV	143	144	146
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/FCF	neg.	neg.	neg.
P/B	neg.	neg.	neg.
P/S	>100	>100	>100
EV/Sales	>100	>100	>100
EV/EBITDA	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

No surprises in the figures

Estimates vs. outcome H1'22

- As expected, the company had no revenue and other operating income was in line with our forecasts (0.5 MEUR).
- Operating loss of EUR 13.4 million was also in line with our estimates, due to costs being at expected level.
- Faron's cash and cash equivalents at the end of the period amounted to EUR 9.9 million, which the company says will be sufficient until Q1'23.
- Cash flow from operating activities was EUR -11.3 million.

Key business events H1'22

- Faron said its plans to refocus the Traumakine research program on the prevention of ischemia-reperfusion-related organ damage and is aiming to start a new study in H1'23.
- The first patient was recruited to the BEXMAB study, which focuses on blood cancers. The first results can be expected towards the end of the year.
- New recruitments strengthened R&D and investor relations capabilities, particularly in the US.
- The company agreed on a debt financing of EUR 30 million and arranged a small directed issue of EUR 5 million during the review period.

Estimates MEUR / EUR	H1'21 Comparison	H1'22 Actualized	H1'22e Inderes	2022e Inderes
Revenue	0.0	0.0	0.0	0.0
EBIT	-10.4	-13.4	-13.4	-22.1
PTP	-10.6	-13.1	-13.5	-22.0
EPS (reported)	-0.20	-0.25	-0.24	-0.40

Source: Inderes

Estimates remained unchanged

Estimate changes

- The H1 report did not give rise to any change in the estimates we published in the recent extensive report.
- We don't expect revenue from the company in 2023-2024.
- Our operating profit estimates also remain unchanged as no new information was received on the cost levels that affect the estimates.

Estimate change drivers

- The results of published research may change our assessment of the probability of commercialization of drug candidates. Changes in probabilities are directly reflected in our estimates.
- The share issue we consider likely would affect our estimates through changes in the financial position and the number of shares
- Potential commercialization agreements would have an impact on the company's financial position and would likely act as a positive drive

Estimate revisions MEUR / EUR	2022e			2023e			2024e		
	Old	New	Change %	Old	New	Change %	Old	New	Change %
Revenue	0.0	0.0		0.0	0.0	0%	0.0	0.0	0%
EBIT	-22.1	-22.1	0%	-0.8	-0.8	0%	-1.7	-1.7	0%
PTP	-22.3	-22.0	-1%	-1.0	-1.1	10%	-1.7	-2.0	18%
EPS (excl. NRIs)	-0.40	-0.40	-1%	-0.02	-0.02	10%	-0.03	-0.04	18%
DPS	0.00	0.00		0.00	0.00		0.00	0.00	

Source: Inderes

No material changes to the valuation

The valuation is based on risk-adjusted estimates

Our valuation is based on risk-adjusted estimates that take into account the binary risk of research failure. We discussed our estimate model in more detail in our recent [extensive report](#). In the absence of revenue and profitability, our valuation is based on the DCF model and peer analysis.

Value of the discounted cash flow model remains unchanged at EUR 2.8

The R&D risk adjusted DCF gives the share a value of EUR 2.8, which is 26% above the market price of the share. Drugs have limited product protection, after which sales and profitability typically decline sharply. Therefore, our DCF model is exceptionally limited in time to 2038, when BEX's patents have expired and no cash flows that are significant to the current value are generated in our estimates. So, we do not make assumptions about terminal growth and profitability, as is typical for the DCF model.

We have used a weighted average cost of capital of 10.6% (WACC). The discount rate is raised by uncertainty of the timing of revenue, the drug's sales price, the achievable revenue, and the terms of possible cooperation agreements, including the royalty percentage. On the other hand, the industry's defensive nature and the strong cash flows resulting from market entry limit the risk level.

Investors should note that there are considerable uncertainties about the realization of estimated cash flows. The DCF model is also very sensitive to the assumptions used, especially when cash flows are far in the future. In the case of Faron, the estimated sales-based cash flows start in 2025 and reach their peak after the mid-2030s. We therefore encourage

investors to compare the assumptions used in the model with their own estimates and required return.

A majority of Faron's current share value (136%) is based on cash flows in 2027-2031. Years 2032-2038 are less important for the current value of cash flows. As future years are loss-making, 2022-2026 cash flows will have a negative impact on the current share value (-67%).

The valuation is in line with the peers

As peer companies, we use listed clinical stage drug development companies in the Nordic countries. We assess the companies' market cap relative to the clinical research stage of their leading drugs. The median market value of the peers is EUR 81 million, below Faron's EUR 122 million. However, we believe Faron deserves a higher valuation than its peers based on its large target market and the potential of its three drug candidate programs. In our view, Faron is neutrally valued relative to its peers.

Recommendation remains the same

Our 12-month target price remains at EUR 2.8, as indicated by the DCF, and we maintain our Accumulate recommendation. Faron is a high-risk investment. Therefore, we remind investors of the importance of diversification, as the failure of drug development can lead to the ultimate loss of invested capital.

Valuation	2022e	2023e	2024e
Share price	2.22	2.22	2.22
Number of shares, millions	55.3	55.3	55.3
Market cap	123	123	123
EV	143	144	146
P/E (adj.)	neg.	neg.	neg.
P/E	neg.	neg.	neg.
P/FCF	neg.	neg.	neg.
P/B	neg.	neg.	neg.
P/S	>100	>100	>100
EV/Sales	>100	>100	>100
EV/EBITDA	neg.	neg.	neg.
EV/EBIT (adj.)	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %
Dividend yield-%	0.0 %	0.0 %	0.0 %

Source: Inderes

Valuation table

Valuation	2017	2018	2019	2020	2021	2022e	2023e	2024e	2025e
Share price			3.30	2.91	3.24	2.22	2.22	2.22	2.22
Number of shares, millions	28.4	31.0	43.3	46.9	53.2	55.3	55.3	55.3	55.3
Market cap			143	136	172	123	123	123	123
EV	-6.9	-1.9	138	135	169	143	144	146	167
P/E (adj.)	0.0	0.0	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/E	0.0	0.0	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/FCF	0.0	0.0	neg.	neg.	neg.	neg.	neg.	neg.	neg.
P/B	0.0	0.0	88.7	neg.	58.8	neg.	neg.	neg.	neg.
P/S		0.0	>100	>100	>100	>100	>100	>100	36.3
EV/Sales		neg.	>100	>100	>100	>100	>100	>100	49.5
EV/EBITDA	0.3	0.1	neg.	neg.	neg.	neg.	neg.	neg.	neg.
EV/EBIT (adj.)	0.3	0.1	neg.	neg.	neg.	neg.	neg.	neg.	neg.
Payout ratio (%)	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Dividend yield-%			0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %

Source: Inderes

Income statement

Income statement	H1'20	H2'20	2020	H1'21	H2'21	2021	H1'22	H2'22e	2022e	H1'23e	H2'23e	2023e	2024e	2025e
Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4
EBITDA	-7.0	-9.4	-16.4	-10.3	-10.5	-20.8	-13.3	-8.6	-21.9	-0.3	-0.3	-0.4	-1.3	-20.2
Depreciation	-0.1	-0.1	-0.3	-0.2	-0.2	-0.3	-0.1	-0.1	-0.2	-0.1	-0.1	-0.4	-0.4	-0.4
EBIT (excl. NRI)	-7.1	-9.5	-16.7	-10.4	-10.7	-21.1	-13.4	-8.7	-22.1	-0.4	-0.4	-0.8	-1.7	-20.6
EBIT	-7.1	-9.5	-16.7	-10.4	-10.7	-21.1	-13.4	-8.7	-22.1	-0.4	-0.4	-0.8	-1.7	-20.6
Share of profits in assoc. compan.	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net financial items	-0.2	-0.1	-0.3	-0.1	0.0	-0.1	0.3	-0.2	0.1	-0.2	-0.2	-0.3	-0.3	-0.3
PTP	-7.3	-9.6	-16.9	-10.6	-10.6	-21.2	-13.1	-8.9	-22.0	-0.6	-0.6	-1.1	-2.0	-20.9
Taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net earnings	-7.3	-9.6	-16.9	-10.6	-10.6	-21.2	-13.1	-8.9	-22.0	-0.6	-0.6	-1.1	-2.0	-20.9
EPS (adj.)	-0.16	-0.20	-0.36	-0.20	-0.20	-0.40	-0.24	-0.16	-0.40	-0.01	-0.01	-0.02	-0.04	-0.38
EPS (rep.)	-0.16	-0.20	-0.36	-0.20	-0.20	-0.40	-0.24	-0.16	-0.40	-0.01	-0.01	-0.02	-0.04	-0.38
Key figures	H1'20	H2'20	2020	H1'21	H2'21	2021	H1'22	H2'22e	2022e	H1'23e	H2'23e	2023e	2024e	2025e
Revenue growth-%			0.0 %			0.0 %			0.0 %			0.0 %	0.0 %	84401.9 %
Adjusted EBIT growth-%	12.6 %	40.7 %	27.1 %	45.9 %	12.4 %	26.7 %	28.2 %	-18.4 %	4.6 %	-97.0 %	-95.3 %	-96.3 %	106.0 %	1129.8 %
Net earnings-%			-423650%			-530225%			-549175%			-27793%	-49301%	-617.2 %

Source: Inderes

Balance sheet

Assets	2020	2021	2022e	2023e	2024e
Non-current assets	0.9	1.1	1.7	1.8	2.0
Goodwill	0.0	0.0	0.0	0.0	0.0
Intangible assets	0.6	0.9	1.0	0.8	0.6
Tangible assets	0.4	0.2	0.7	1.0	1.3
Associated companies	0.0	0.0	0.0	0.0	0.0
Other investments	0.0	0.0	0.0	0.0	0.0
Other non-current assets	0.0	0.0	0.0	0.0	0.0
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Current assets	7.4	12.1	0.0	0.0	0.0
Inventories	0.0	0.0	0.0	0.0	0.0
Other current assets	0.0	0.0	0.0	0.0	0.0
Receivables	3.3	5.2	0.0	0.0	0.0
Cash and equivalents	4.1	6.9	0.0	0.0	0.0
Balance sheet total	8.4	13.2	1.7	1.8	2.0

Source: Inderes

Liabilities & equity	2020	2021	2022e	2023e	2024e
Equity	-1.9	2.9	-19.1	-20.2	-22.1
Share capital	2.7	2.7	2.7	2.7	2.7
Retained earnings	-96.6	-116.3	-138.3	-139.4	-141.3
Hybrid bonds	0.0	0.0	0.0	0.0	0.0
Revaluation reserve	0.0	0.0	0.0	0.0	0.0
Other equity	92.0	117	117	117	117
Minorities	0.0	0.0	0.0	0.0	0.0
Non-current liabilities	3.7	3.1	0.5	0.5	0.5
Deferred tax liabilities	0.0	0.0	0.0	0.0	0.0
Provisions	0.0	0.0	0.0	0.0	0.0
Long term debt	2.7	2.9	0.0	0.0	0.0
Convertibles	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	1.0	0.2	0.5	0.5	0.5
Current liabilities	6.4	7.2	20.2	21.4	23.6
Short term debt	0.0	0.4	20.2	21.4	23.6
Payables	6.4	6.7	0.0	0.0	0.0
Other current liabilities	0.0	0.0	0.0	0.0	0.0
Balance sheet total	8.3	13.2	1.7	1.8	2.0

Summary

Income statement	2019	2020	2021	2022e	2023e	Per share data	2019	2020	2021	2022e	2023e
Revenue	0.0	0.0	0.0	0.0	0.0	EPS (reported)	-0.31	-0.36	-0.40	-0.40	-0.02
EBITDA	-12.9	-16.4	-20.8	-22.1	-0.4	EPS (adj.)	-0.31	-0.36	-0.40	-0.40	-0.02
EBIT	-13.1	-16.7	-21.1	-22.1	-0.8	OCF / share	-0.27	-0.36	-0.42	-0.43	-0.01
PTP	-13.3	-16.9	-21.2	-22.0	-1.1	FCF / share	-0.27	-0.35	-0.44	-0.43	-0.02
Net Income	-13.3	-16.9	-21.2	-22.0	-1.1	Book value / share	0.04	-0.04	0.06	-0.34	-0.37
Extraordinary items	0.0	0.0	0.0	0.0	0.0	Dividend / share	0.00	0.00	0.00	0.00	0.00
Balance sheet	2019	2020	2021	2022e	2023e	Growth and profitability	2019	2020	2021	2022e	2023e
Balance sheet total	10.2	8.4	13.2	1.7	1.8	Revenue growth-%	-79%	0%	0%	0%	0%
Equity capital	1.6	-1.9	2.9	-19.1	-20.2	EBITDA growth-%	-35%	27%	27%	6%	-98%
Goodwill	0.0	0.0	0.0	0.0	0.0	EBIT (adj.) growth-%	-34%	27%	27%	5%	-96%
Net debt	-4.6	-1.4	-3.5	20.2	21.4	EPS (adj.) growth-%	-53%	18%	10%	0%	-95%
Cash flow	2019	2020	2021	2022e	2023e	EBITDA-%	-321575%	-409275%	-520050%	-553250%	-10420%
EBITDA	-12.9	-16.4	-20.8	-22.1	-0.4	EBIT (adj.)-%	-327525%	-416350%	-527700%	-551975%	-20293%
Change in working capital	1.0	-0.7	-1.5	-1.5	0.0	EBIT-%	-327525%	-416350%	-527700%	-551975%	-20293%
Operating cash flow	-11.8	-17.1	-22.4	-23.7	-0.4	ROE-%	-1340.3 %	14063.1 %	-3920.3 %	272.7 %	5.7 %
CAPEX	-0.1	-0.2	-0.5	-0.5	-0.5	ROI-%	-400.8 %	-676.3 %	-588.9 %	-593.8 %	-66.7 %
Free cash flow	-11.7	-16.6	-23.6	-23.8	-0.9	Equity ratio	15.8 %	-22.1 %	22.3 %	-1150.3 %	-1135.1 %
						Gearing	-287.8 %	73.9 %	-119.5 %	-106.1 %	-106.3 %
Valuation multiples	2019	2020	2021	2022e	2023e						
EV/S	>100	>100	>100	>100	>100						
EV/EBITDA (adj.)	neg.	neg.	neg.	neg.	neg.						
EV/EBIT (adj.)	neg.	neg.	neg.	neg.	neg.						
P/E (adj.)	neg.	neg.	neg.	neg.	neg.						
P/B	88.7	neg.	58.8	neg.	neg.						
Dividend-%	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %						

Source: Inderes

Disclaimer and recommendation history

The information presented in Inderes reports is obtained from several different public sources that Inderes considers to be reliable. Inderes aims to use reliable and comprehensive information, but Inderes does not guarantee the accuracy of the presented information. Any opinions, estimates and forecasts represent the views of the authors. Inderes is not responsible for the content or accuracy of the presented information. Inderes and its employees are also not responsible for the financial outcomes of investment decisions made based on the reports or any direct or indirect damage caused by the use of the information. The information used in producing the reports may change quickly. Inderes makes no commitment to announcing any potential changes to the presented information and opinions.

The reports produced by Inderes are intended for informational use only. The reports should not be construed as offers or advice to buy, sell or subscribe investment products. Customers should also understand that past performance is not a guarantee of future results. When making investment decisions, customers must base their decisions on their own research and their estimates of the factors that influence the value of the investment and take into account their objectives and financial position and use advisors as necessary. Customers are responsible for their investment decisions and their financial outcomes.

Reports produced by Inderes may not be edited, copied or made available to others in their entirety, or in part, without Inderes' written consent. No part of this report, or the report as a whole, shall be transferred or shared in any form to the United States, Canada or Japan or the citizens of the aforementioned countries. The legislation of other countries may also lay down restrictions pertaining to the distribution of the information contained in this report. Any individuals who may be subject to such restrictions must take said restrictions into account.

Inderes issues target prices for the shares it follows. The recommendation methodology used by Inderes is based on the share's 12-month expected total shareholder return (including the share price and dividends) and takes into account Inderes' view of the risk associated with the expected returns. The recommendation policy consists of four tiers: Sell, Reduce, Accumulate and Buy. As a rule, Inderes' investment recommendations and target prices are reviewed at least 2–4 times per year in connection with the companies' interim reports, but the recommendations and target prices may also be changed at other times depending on the market conditions. The issued recommendations and target prices do not guarantee that the share price will develop in line with the estimate. Inderes primarily uses the following valuation methods in determining target prices and recommendations: Cash flow analysis (DCF), valuation multiples, peer group analysis and sum of parts analysis. The valuation methods and target price criteria used are always company-specific and they may vary significantly depending on the company and (or) industry.

Inderes' recommendation policy is based on the following distribution relative to the 12-month risk-adjusted expected total shareholder return.

Buy The 12-month risk-adjusted expected shareholder

return of the share is very attractive

Accumulate The 12-month risk-adjusted expected shareholder return of the share is attractive

Reduce The 12-month risk-adjusted expected shareholder return of the share is weak

Sell The 12-month risk-adjusted expected shareholder return of the share is very weak

The assessment of the 12-month risk-adjusted expected total shareholder return based on the above-mentioned definitions is company-specific and subjective. Consequently, similar 12-month expected total shareholder returns between different shares may result in different recommendations, and the recommendations and 12-month expected total shareholder returns between different shares should not be compared with each other. The counterpart of the expected total shareholder return is Inderes' view of the risk taken by the investor, which varies considerably between companies and scenarios. Thus, a high expected total shareholder return does not necessarily lead to positive performance when the risks are exceptionally high and, correspondingly, a low expected total shareholder return does not necessarily lead to a negative recommendation if Inderes considers the risks to be moderate.

The analysts who produce Inderes' research and Inderes employees cannot have 1) shareholdings that exceed the threshold of significant financial gain or 2) shareholdings exceeding 1% in any company subject to Inderes' research activities. Inderes Oyj can only own shares in the target companies it follows to the extent shown in the company's model portfolio investing real funds. All of Inderes Oyj's shareholdings are presented in itemised form in the model portfolio. Inderes Oyj does not have other shareholdings in the target companies analysed. The remuneration of the analysts who produce the analysis are not directly or indirectly linked to the issued recommendation or views. Inderes Oyj does not have investment bank operations.

Inderes or its partners whose customer relationships may have a financial impact on Inderes may, in their business operations, seek assignments with various issuers with respect to services provided by Inderes or its partners. Thus, Inderes may be in a direct or indirect contractual relationship with an issuer that is the subject of research activities. Inderes and its partners may provide investor relations services to issuers. The aim of such services is to improve communication between the company and the capital markets. These services include the organisation of investor events, advisory services related to investor relations and the production of investor research reports.

More information about research disclaimers can be found at www.inderes.fi/research-disclaimer.

Inderes has made an agreement with the issuer and target of this report, which entails compiling a research report.

Recommendation history (>12 mo)

Date	Recommendation	Target price	Share price
8/8/2022	Accumulate	2.80 €	2.44 €
8/26/2022	Accumulate	2.80 €	0.00 €



Inderes' mission is to connect listed companies and investors. We produce high-quality research and content for the needs of our extensive investor community.

At Inderes we believe that open data is every investor's fundamental right. We guarantee investors' access to award-winning research, insightful video content and an active investor community.

For listed companies we ensure that there is always high-quality information available on the company for investors and shareholders for decision making, and that data collected from investors can be utilized by the companies.

Over 100 Finnish listed companies want to serve their shareholders and investors through us by utilizing our company research services, data driven IR services, content creation and consulting.

Inderes Oyj

Itämerentori 2

FI-00180 Helsinki, Finland

+358 10 219 4690

Award-winning research at [inderes.fi](https://www.inderes.fi)



STARMINE
ANALYST AWARDS
FROM REFINITIV



THOMSON REUTERS
ANALYST AWARDS



Juha Kinnunen
2012, 2016, 2017, 2018, 2019, 2020



Mikael Rautanen
2014, 2016, 2017, 2019



Sauli Vilén
2012, 2016, 2018, 2019, 2020



Antti Viljakainen
2014, 2015, 2016, 2018, 2019, 2020



Olli Koponen
2020



Joni Grönqvist
2019, 2020



Erkki Vesola
2018, 2020



Petri Gostowski
2020



Atte Riikola
2020

**Research belongs
to everyone.**